Wegovy® will be the preferred GLP-1 medicine for obesity on the largest commercial template formularies for CVS Caremark, the largest Pharmacy Benefit Manager (PBM) in the US, effective July 1, 2025 Novo Nordisk is focused on new ways to drive access and affordability for Wegovy®, the...
Read More Details
Finally We wish PressBee provided you with enough information of ( Novo Nordisk announces that CVS Caremark®, the country's largest PBM, has decided Wegovy® will be the preferred GLP-1 medicine covered for obesity on its template formularies )
Also on site :
- Starmer will slash firms’ energy bills amid warnings net zero costs are crippling British industry
- Judge orders Kilmar Abrego Garcia’s release from jail before trial, but ICE plans to detain him
- Diamondbacks Sign James McCann